ABOUT EVENT

Why Attend?

The 6th Dermatology Drug Development Summit Europe returns in less than a week, and continues to be the go-to meeting for biopharma leaders shaping the future of immunodermatology. As modalities diversify, targeted indications expand, and inflammatory pathways are increasingly elucidated, the need to differentiate your pipelines in an evolving landscape has never been greater.

Here are some highlights from this year's agenda:

  • Gain cutting-edge disease biology insights with a presentation from Noa Therapeutics’ CSO, Serene Mandla: "Biological Crossovers: Uncovering Disease Targets with Biological Relevance Across Multiple Diseases."
  • Hear diverse perspectives on the challenges of designing trials for Hidradenitis Suppurativa, considering varied endpoint requirements across different regulatory environments. The panel features C-level representatives from biotechs including Moonlake Immunotherapeutics, InflaRx, and Citryll Therapeutics.
  • Explore new immuno-dermatology modalities, including a presentation on gene-silencing siRNA biologics from Lars French, CMO of Alys Pharmaceuticals.
DOWNLOAD EVENT GUIDE

What Will You Gain?

Stay ahead in immunodermatology innovation by uncovering the latest therapeutic advancements beyond small molecules and monoclonal antibodies. 

Optimise clinical trial strategies with insights into patient stratification, regulatory approval, and endpoint selection. 

Tackle recruitment and regulatory challenges with expert-led discussions on streamlining clinical development and accelerating trial timelines. 

Connect with 80+ industry leaders to forge new partnerships and gain exclusive insights into emerging trends and future opportunities. 

Who Will You Meet?

Senior Leaders in R&D, Clinical Development, Medical Affairs, and Regulatory Affairs unite to overcome shared challenges and advance their immunodermatology pipelines at the leading Dermatology Pharma Summit.

What Your Peers Have to Say

“Excellent networking with colleges who are really dedicated to dermatology drug development.” - Eurofins

“I enjoyed attending and speaking at Hanson Wade summit. It is a great way to network. I enjoy the round table discussions and exposure to various facets of drug discovery.” - Merck & Co

“The intimate and transparent atmosphere, the dedicated networking sessions, the relevance & quality of the presentations and the number of dermatology leaders attending were all great.” - Sanos Group

Seniorities attending

"The format really favours networking, the congress has a reasonable size enabling discussion with everyone" - Nuvisan Pharma Services Group 

“The Dermatology Drug Development Summit is a vibrant forum for the presentation of innovation and ideas amongst experts who understand the unique opportunities and challenges of treating dermatologic disease" - Arcutis Biotherapeutics 

Previously Attending Companies Include:

2025 EVENT GUIDE
REGISTER INTEREST
PARTNER